<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3781">
  <stage>Registered</stage>
  <submitdate>18/01/2013</submitdate>
  <approvaldate>18/01/2013</approvaldate>
  <nctid>NCT01776528</nctid>
  <trial_identification>
    <studytitle>Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants</studytitle>
    <scientifictitle>A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>12-0101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - NGM282
Other interventions - Placebo

Experimental: Cohort 1 SAD - NGM282 Dose 1 vs Placebo

Experimental: Cohort 2 SAD - NGM282 Dose 2 vs Placebo

Experimental: Cohort 3 SAD - NGM282 Dose 3 vs Placebo

Experimental: Cohort 4 SAD - NGM282 Dose 4 vs Placebo

Experimental: Cohort 5 SAD - NGM282 Dose 5 vs Placebo

Experimental: Cohort 6 SAD - NGM282 Dose 6 vs Placebo

Experimental: Cohort 7 MAD - NGM282 Dose 1 vs Placebo

Experimental: Cohort 8 MAD - NGM282 Dose 2 vs Placebo

Experimental: Cohort 9 MAD - NGM282 Dose 3 vs Placebo

Experimental: Cohort 10 MAD - NGM282 Dose 4 vs Placebo

Experimental: Cohort 11 MAD - NGM282 Dose 5 vs Placebo

Experimental: Cohort 12 MAD - NGM282 Dose 6 vs Placebo


Other interventions: NGM282


Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability - To evaluate the safety and tolerability of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</outcome>
      <timepoint>7 days and 14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics - To evaluate the pharmacokinetics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</outcome>
      <timepoint>7 days and 14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics - To evaluate the pharmacodynamics of single ascending doses and multiple ascending doses of NGM282 in healthy adult participants.</outcome>
      <timepoint>7 days and 14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males or females, between 18 and 65 years of age, inclusive

          -  BMI range is 20-35 kg/m2, inclusive for the SAD Module, and 25-35 kg/m2, inclusive for
             the MAD Module at Screening;

          -  In good health, determined by no clinically significant findings from medical history,
             physical exam, 12 lead ECG, clinical laboratory findings, and vital signs at Screening
             and Day -1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,
             neurological, or psychiatric disorder (as determined by the PI)

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>119</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>NGM Clinical Study Site - Perth</hospital>
    <postcode>6009 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>NGM Biopharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety and tolerability of NGM282, both single
      dose and multiple doses, in normal healthy adult participants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01776528</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alex M DePaoli, MD</name>
      <address>NGM Biopharmaceuticals, Inc</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>